Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3357697 | 0.81 | KCNA3 (0.58) | TDP1LTA4H | |
| SCHEMBL10607155 | 0.78 | RARB (0.54) | TDP1MAPK1RARBEPHX2L3MBTL1 | |
| SCHEMBL98351 | 0.76 | LTA4H (0.57) | LTA4H | |
| SCHEMBL19549608 | 0.74 | TDP1 (0.50) | TDP1KMT2AMAPK1RARBEPHX2 | |
| SCHEMBL22282470 | 0.74 | TDP1 (0.50) | TDP1KMT2AMAPK1RARBEPHX2 | |
| SCHEMBL15301868 | 0.74 | TDP1 (0.50) | TDP1KMT2AMAPK1RARBEPHX2 | |
| SCHEMBL22579845 | 0.73 | DRD2 (0.48) | TDP1MEN1KMT2AMAPK1EPHX2 | |
| SCHEMBL1119457 | 0.72 | NR5A1 (0.62) | RARBLTA4H | |
| SCHEMBL27111189 | 0.72 | TDP1 (0.52) | TDP1MEN1KMT2AMAPK1EPHX2 | |
| SCHEMBL910297 | 0.71 | LTA4H (0.55) | MEN1KMT2AMAPK1L3MBTL1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | KAHNE DANIEL (US) | 2004-06-10 | — | — | US | disclosed |
| US-6699836-B2 | Vancomycin analogs | THE TRUSTEES OF PRINCETON UNIVERSITY | 2004-03-02 | — | — | US | disclosed |
| EP-0667353-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6518243-B1 | Desleucyl glycopeptide antibiotics and methods of making same | TRUSTEES OF PRINCETON UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| US-20020042365-A1 | Vancomycin analogs | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2002-04-11 | — | — | US | disclosed |
| EP-1016670-A1 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | FUT6, FUT5, ST6GAL1 | TDP1 2916/4885MEN1 1692/4885KMT2A 3866/4885 |
| US-20020042365-A1 | Vancomycin analogs | VNN1, PTMS, ASNS | TDP1 4793/4885MEN1 1737/4885KMT2A 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.